21 documents

Read All
20:19 , Nov 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Cell culture and mouse studies identified an indole-dihydropyrazine-based MCL1 inhibitor that could help treat AML in combination with Venclyxto venetoclax. In mononuclear bone marrow cells from six AML patients who...
Read More
19:12 , Feb 21, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest combining MCL1 inhibitors with inducers of double-strand break stress could help treat NSCLC. In an irradiated human NSCLC cell line, MCL1 knockout decreased...
Read More
00:39 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); multiple myeloma (MM) In vitro and cell culture studies suggest stapled peptide inhibitors of MCL1 could help treat ALL and MM. Modification of previously identified peptide-based inhibitors of MCL1 with...
Read More
00:30 , Oct 12, 2017 |  BC Innovations  |  Product R&D

Artificial mini proteins

Virvio Inc. has spun out of a group from the University of Washington to develop artificial mini proteins as novel influenza therapeutics. The mini proteins, typically ranging between 30 and 50 amino acids in length,...
Read More
19:14 , Aug 22, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting MCL1 could help treat triple-negative breast cancer (TNBC) and HER2 -amplified breast cancer. In breast cancer patient samples, levels of MCL1 were higher...
Read More
23:34 , Jun 15, 2017 |  BC Innovations  |  Tools & Techniques

Breaking the barrier

A three-way deal between Amgen Inc. , Feldan Therapeutics Inc. and Elasmogen Ltd. is the latest cause for optimism that technologies are finally converging to enable the generation of cell-penetrating biologics. The biotechs join a...
Read More
07:00 , Sep 22, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Myeloid leukemia cell differentiation protein (MCL1); eukaryotic translation initiation factor 4B (EIF4B)

Cancer INDICATION: Breast cancer Patient sample and cell studies suggest inhibiting EIF4B or MCL1 could help treat basal breast cancer. In tumor samples from breast cancer patients, MCL1 levels were higher in the aggressive basal...
Read More
08:00 , Jan 11, 2016 |  BC Week In Review  |  Company News

Merck, Complix deal

Complix partnered with Merck to discover and develop cancer treatments using Complix’s Cell-Penetrating Alphabodies (CPABs) technology. Complix will use its Alphabody platform to deliver CPABs against up to two undisclosed cancer targets from Merck, which...
Read More
01:32 , Jan 7, 2016 |  BC Extra  |  Company News

Merck, Complix in cancer discovery deal

Complix N.V. (Diepenbeek, Belgium) partnered with Merck & Co. Inc. (NYSE:MRK) to develop Cell-Penetrating Alphabodies (CPABs) against up to two undisclosed intracellular cancer targets. Complix said it is eligible for $280 million, including an undisclosed...
Read More
02:25 , Nov 11, 2015 |  BC Extra  |  Company News

Management tracks

Tauopathy therapeutic developer Asceneuron S.A. (Lausanne, Switzerland) appointed Hans Schikan chairman. Schikan is chairman of Complix N.V. (Diepenbeek, Belgium) and InteRNA Technologies B.V. (Nijmegen, the Netherlands) and previously was CEO of Prosensa Holding N.V. ,...
Read More